The prognostic role of Ki67, p53, Her2, and CyD1 immunohistochemical markers in recurrent parasagittal meningiomas
Objective. Determine the role of Ki67, p53, Her2, and CyD1 immunohistochemical markers in predicting the recurrence of parasagittal meningiomas Materials and Methods. The immunohistochemical (IHC) study was conducted in 26 parasagittal meningioma (PM) patients aged 36 to 72, who were trea...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Romodanov Neurosurgery Institute
2023-06-01
|
| Series: | Ukrainian Neurosurgical Journal |
| Online Access: | https://theunj.org/article/view/276874 |
| _version_ | 1797351409003266048 |
|---|---|
| author | Andrii H. Sirko Ihor S. Shponka Vadym A. Perepelytsia Iryna O. Molokova |
| author_facet | Andrii H. Sirko Ihor S. Shponka Vadym A. Perepelytsia Iryna O. Molokova |
| author_sort | Andrii H. Sirko |
| collection | DOAJ |
| description |
Objective. Determine the role of Ki67, p53, Her2, and CyD1 immunohistochemical markers in predicting the recurrence of parasagittal meningiomas
Materials and Methods. The immunohistochemical (IHC) study was conducted in 26 parasagittal meningioma (PM) patients aged 36 to 72, who were treated in the Mechnikov Dnipropetrovsk Regional Clinical Hospital from 2000 to 2021 inclusive. 26 patients were divided into 2 equal groups with the most similar characteristics (patient’s gender, age, and meningioma malignancy as of the time of primary surgery) using the balancing method (pairwise selection). The study group consisted of 13 (50%) patients with detected postoperative PM recurrence/prolonged growth, while the control group included the remaining 13 (50%) patients with no PM recurrence. To evaluate prospects of further studies, the expression of the following markers by the tumor was analyzed: cell proliferation (Ki67), genome stability (p53 protein), dysfunction of epidermal growth factor signaling pathways (ERBB2 or Her-2/neu (Her2)), and cell cycle regulators (cyclin D1 (CyD1)).
Results. An association between the PM’s high proliferative activity and its recurrence was moderate (rs=0.44, р=0.025). Median Ki-67 in the study PM group (with recurrence) was three times higher than that in the control group (no recurrence) — 6.0% (4.0%; 9.0%) vs. 2.0% (0.5%; 4.5%) (p=0.029). In the case of Ki67 expression > 4.5%, the risk of PM recurrence/prolonged growth increased by 7.5 times (OR=7.5; 95% CI (1.3–43.0)) (area under the ROC curve, AUC=0.751 (95% CI, 0.544–0.898), p=0.011). The comparative and correlation analysis found no significant association between the p53 protein mutation and the PM recurrence (rs=0.23, р=0.254). Neither we found a significant association between the PM recurrence and the CyD1 expression (rs=0.29, р=0.147) or severity (rs=-0.08, р=0.696). The correlation between the Her2 expression in the PM cells and the PM recurrence was insignificant (rs=0.23, р=0.251). The primary PM malignancy (Grade II–III) increases the risk of unfavorable prognosis by 5.3 times (95% CI, 1.0–29.4) (AUC= 0.722) (95% CI, 0.513–0.878); p=0.016, sensitivity= 61.5%, specificity= 76.9%.
Conclusions. The following can be considered probable predictors of the PM recurrence after the primary surgery (within 20 years of follow-up): Ki67 proliferation index > 4.5% and grade II–III tumor malignancy. The comparative and correlation analysis found no statistically significant association between the tumor recurrence and the p53, Her2, and CyD1 immunohistochemical markers. However, the detected significant correlation between the p53, Her2, and CyD1 markers expression and the Ki67 proliferative index and tumor malignancy requires further research with a larger number of clinical observations. |
| first_indexed | 2024-03-08T12:59:04Z |
| format | Article |
| id | doaj.art-1fd03ceddef34108850e1f534c198623 |
| institution | Directory Open Access Journal |
| issn | 2663-9084 2663-9092 |
| language | English |
| last_indexed | 2024-03-08T12:59:04Z |
| publishDate | 2023-06-01 |
| publisher | Romodanov Neurosurgery Institute |
| record_format | Article |
| series | Ukrainian Neurosurgical Journal |
| spelling | doaj.art-1fd03ceddef34108850e1f534c1986232024-01-19T11:04:08ZengRomodanov Neurosurgery InstituteUkrainian Neurosurgical Journal2663-90842663-90922023-06-01292354210.25305/unj.276874The prognostic role of Ki67, p53, Her2, and CyD1 immunohistochemical markers in recurrent parasagittal meningiomasAndrii H. Sirko0https://orcid.org/0000-0001-6536-2035Ihor S. Shponka1https://orcid.org/0000-0002-7561-6489Vadym A. Perepelytsia2https://orcid.org/0000-0001-9336-5639Iryna O. Molokova3https://orcid.org/0000-0001-9702-7434Department of Nervous Diseases and Neurosurgery, Dnipro State Medical University, Dnipro,Center for Cerebral Neurosurgery, Mechnikov Dnipropetrovsk Regional Clinical Hospital, Dnipro , UkraineDepartment of Pathological Anatomy, Forensic Medicine and Pathological Physiology, Dnipro State Medical University, Dnipro, UkraineDepartment of Nervous Diseases and Neurosurgery, Dnipro State Medical University, Dnipro, Endovascular Center, Mechnikov Dnipropetrovsk Regional Clinical Hospital, Dnipro, UkraineDepartment of Pathological Anatomy, Forensic Medicine and Pathological Physiology, Dnipro State Medical University, Dnipro, Ukraine Objective. Determine the role of Ki67, p53, Her2, and CyD1 immunohistochemical markers in predicting the recurrence of parasagittal meningiomas Materials and Methods. The immunohistochemical (IHC) study was conducted in 26 parasagittal meningioma (PM) patients aged 36 to 72, who were treated in the Mechnikov Dnipropetrovsk Regional Clinical Hospital from 2000 to 2021 inclusive. 26 patients were divided into 2 equal groups with the most similar characteristics (patient’s gender, age, and meningioma malignancy as of the time of primary surgery) using the balancing method (pairwise selection). The study group consisted of 13 (50%) patients with detected postoperative PM recurrence/prolonged growth, while the control group included the remaining 13 (50%) patients with no PM recurrence. To evaluate prospects of further studies, the expression of the following markers by the tumor was analyzed: cell proliferation (Ki67), genome stability (p53 protein), dysfunction of epidermal growth factor signaling pathways (ERBB2 or Her-2/neu (Her2)), and cell cycle regulators (cyclin D1 (CyD1)). Results. An association between the PM’s high proliferative activity and its recurrence was moderate (rs=0.44, р=0.025). Median Ki-67 in the study PM group (with recurrence) was three times higher than that in the control group (no recurrence) — 6.0% (4.0%; 9.0%) vs. 2.0% (0.5%; 4.5%) (p=0.029). In the case of Ki67 expression > 4.5%, the risk of PM recurrence/prolonged growth increased by 7.5 times (OR=7.5; 95% CI (1.3–43.0)) (area under the ROC curve, AUC=0.751 (95% CI, 0.544–0.898), p=0.011). The comparative and correlation analysis found no significant association between the p53 protein mutation and the PM recurrence (rs=0.23, р=0.254). Neither we found a significant association between the PM recurrence and the CyD1 expression (rs=0.29, р=0.147) or severity (rs=-0.08, р=0.696). The correlation between the Her2 expression in the PM cells and the PM recurrence was insignificant (rs=0.23, р=0.251). The primary PM malignancy (Grade II–III) increases the risk of unfavorable prognosis by 5.3 times (95% CI, 1.0–29.4) (AUC= 0.722) (95% CI, 0.513–0.878); p=0.016, sensitivity= 61.5%, specificity= 76.9%. Conclusions. The following can be considered probable predictors of the PM recurrence after the primary surgery (within 20 years of follow-up): Ki67 proliferation index > 4.5% and grade II–III tumor malignancy. The comparative and correlation analysis found no statistically significant association between the tumor recurrence and the p53, Her2, and CyD1 immunohistochemical markers. However, the detected significant correlation between the p53, Her2, and CyD1 markers expression and the Ki67 proliferative index and tumor malignancy requires further research with a larger number of clinical observations.https://theunj.org/article/view/276874 |
| spellingShingle | Andrii H. Sirko Ihor S. Shponka Vadym A. Perepelytsia Iryna O. Molokova The prognostic role of Ki67, p53, Her2, and CyD1 immunohistochemical markers in recurrent parasagittal meningiomas Ukrainian Neurosurgical Journal |
| title | The prognostic role of Ki67, p53, Her2, and CyD1 immunohistochemical markers in recurrent parasagittal meningiomas |
| title_full | The prognostic role of Ki67, p53, Her2, and CyD1 immunohistochemical markers in recurrent parasagittal meningiomas |
| title_fullStr | The prognostic role of Ki67, p53, Her2, and CyD1 immunohistochemical markers in recurrent parasagittal meningiomas |
| title_full_unstemmed | The prognostic role of Ki67, p53, Her2, and CyD1 immunohistochemical markers in recurrent parasagittal meningiomas |
| title_short | The prognostic role of Ki67, p53, Her2, and CyD1 immunohistochemical markers in recurrent parasagittal meningiomas |
| title_sort | prognostic role of ki67 p53 her2 and cyd1 immunohistochemical markers in recurrent parasagittal meningiomas |
| url | https://theunj.org/article/view/276874 |
| work_keys_str_mv | AT andriihsirko theprognosticroleofki67p53her2andcyd1immunohistochemicalmarkersinrecurrentparasagittalmeningiomas AT ihorsshponka theprognosticroleofki67p53her2andcyd1immunohistochemicalmarkersinrecurrentparasagittalmeningiomas AT vadymaperepelytsia theprognosticroleofki67p53her2andcyd1immunohistochemicalmarkersinrecurrentparasagittalmeningiomas AT irynaomolokova theprognosticroleofki67p53her2andcyd1immunohistochemicalmarkersinrecurrentparasagittalmeningiomas AT andriihsirko prognosticroleofki67p53her2andcyd1immunohistochemicalmarkersinrecurrentparasagittalmeningiomas AT ihorsshponka prognosticroleofki67p53her2andcyd1immunohistochemicalmarkersinrecurrentparasagittalmeningiomas AT vadymaperepelytsia prognosticroleofki67p53her2andcyd1immunohistochemicalmarkersinrecurrentparasagittalmeningiomas AT irynaomolokova prognosticroleofki67p53her2andcyd1immunohistochemicalmarkersinrecurrentparasagittalmeningiomas |